154 related articles for article (PubMed ID: 28125165)
1. Inhibitor Selectivity for Cyclin-Dependent Kinase 7: A Structural, Thermodynamic, and Modelling Study.
Hazel P; Kroll SH; Bondke A; Barbazanges M; Patel H; Fuchter MJ; Coombes RC; Ali S; Barrett AG; Freemont PS
ChemMedChem; 2017 Mar; 12(5):372-380. PubMed ID: 28125165
[TBL] [Abstract][Full Text] [Related]
2. Reciprocal activation by cyclin-dependent kinases 2 and 7 is directed by substrate specificity determinants outside the T loop.
Garrett S; Barton WA; Knights R; Jin P; Morgan DO; Fisher RP
Mol Cell Biol; 2001 Jan; 21(1):88-99. PubMed ID: 11113184
[TBL] [Abstract][Full Text] [Related]
3. CDK4 T172 phosphorylation is central in a CDK7-dependent bidirectional CDK4/CDK2 interplay mediated by p21 phosphorylation at the restriction point.
Bisteau X; Paternot S; Colleoni B; Ecker K; Coulonval K; De Groote P; Declercq W; Hengst L; Roger PP
PLoS Genet; 2013 May; 9(5):e1003546. PubMed ID: 23737759
[TBL] [Abstract][Full Text] [Related]
4. Recognition of Cdk2 by Cdk7.
Lolli G; Johnson LN
Proteins; 2007 Jun; 67(4):1048-59. PubMed ID: 17373709
[TBL] [Abstract][Full Text] [Related]
5. The amino terminus of Cdk2 binds p21.
Moskowitz NK; Borao FJ; Dardashti O; Cohen HD; Germino FJ
Oncol Res; 1996; 8(9):343-52. PubMed ID: 8979268
[TBL] [Abstract][Full Text] [Related]
6. Cyclin-dependent kinase-2 (Cdk2) forms an inactive complex with cyclin D1 since Cdk2 associated with cyclin D1 is not phosphorylated by Cdk7-cyclin-H.
Higashi H; Suzuki-Takahashi I; Saitoh S; Segawa K; Taya Y; Okuyama A; Nishimura S; Kitagawa M
Eur J Biochem; 1996 Apr; 237(2):460-7. PubMed ID: 8647086
[TBL] [Abstract][Full Text] [Related]
7. Molecular simulation studies on the binding selectivity of 2-anilino-4-(thiazol-5-yl)-pyrimidines in complexes with CDK2 and CDK7.
Chohan TA; Qian HY; Pan YL; Chen JZ
Mol Biosyst; 2016 Jan; 12(1):145-61. PubMed ID: 26565382
[TBL] [Abstract][Full Text] [Related]
8. 2.5 Å-resolution structure of human CDK-activating kinase bound to the clinical inhibitor ICEC0942.
Greber BJ; Remis J; Ali S; Nogales E
Biophys J; 2021 Feb; 120(4):677-686. PubMed ID: 33476598
[TBL] [Abstract][Full Text] [Related]
9. The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity.
Ali S; Heathcote DA; Kroll SH; Jogalekar AS; Scheiper B; Patel H; Brackow J; Siwicka A; Fuchter MJ; Periyasamy M; Tolhurst RS; Kanneganti SK; Snyder JP; Liotta DC; Aboagye EO; Barrett AG; Coombes RC
Cancer Res; 2009 Aug; 69(15):6208-15. PubMed ID: 19638587
[TBL] [Abstract][Full Text] [Related]
10. Design and Synthesis of Novel Macrocyclic Derivatives as Potent and Selective Cyclin-Dependent Kinase 7 Inhibitors.
Niu P; Tao Y; Lin G; Xu H; Meng Q; Yang K; Huang W; Song M; Ding K; Ma D; Fan M
J Med Chem; 2024 Apr; 67(8):6099-6118. PubMed ID: 38586950
[TBL] [Abstract][Full Text] [Related]
11. ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment.
Patel H; Periyasamy M; Sava GP; Bondke A; Slafer BW; Kroll SHB; Barbazanges M; Starkey R; Ottaviani S; Harrod A; Aboagye EO; Buluwela L; Fuchter MJ; Barrett AGM; Coombes RC; Ali S
Mol Cancer Ther; 2018 Jun; 17(6):1156-1166. PubMed ID: 29545334
[TBL] [Abstract][Full Text] [Related]
12. The effects of changing the site of activating phosphorylation in CDK2 from threonine to serine.
Kaldis P; Cheng A; Solomon MJ
J Biol Chem; 2000 Oct; 275(42):32578-84. PubMed ID: 10931829
[TBL] [Abstract][Full Text] [Related]
13. The cyclin-dependent kinase (CDK) family member PNQALRE/CCRK supports cell proliferation but has no intrinsic CDK-activating kinase (CAK) activity.
Wohlbold L; Larochelle S; Liao JC; Livshits G; Singer J; Shokat KM; Fisher RP
Cell Cycle; 2006 Mar; 5(5):546-54. PubMed ID: 16552187
[TBL] [Abstract][Full Text] [Related]
14. The crystal structure of human CDK7 and its protein recognition properties.
Lolli G; Lowe ED; Brown NR; Johnson LN
Structure; 2004 Nov; 12(11):2067-79. PubMed ID: 15530371
[TBL] [Abstract][Full Text] [Related]
15. Requirements for Cdk7 in the assembly of Cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells.
Larochelle S; Merrick KA; Terret ME; Wohlbold L; Barboza NM; Zhang C; Shokat KM; Jallepalli PV; Fisher RP
Mol Cell; 2007 Mar; 25(6):839-50. PubMed ID: 17386261
[TBL] [Abstract][Full Text] [Related]
16. Cyclin-dependent kinase 7 inhibitors in cancer therapy.
Wang M; Wang T; Zhang X; Wu X; Jiang S
Future Med Chem; 2020 May; 12(9):813-833. PubMed ID: 32208930
[TBL] [Abstract][Full Text] [Related]
17. Characterization of new highly selective pyrazolo[4,3-d]pyrimidine inhibitor of CDK7.
Kovalová M; Havlíček L; Djukic S; Škerlová J; Peřina M; Pospíšil T; Řezníčková E; Řezáčová P; Jorda R; Kryštof V
Biomed Pharmacother; 2023 May; 161():114492. PubMed ID: 36931035
[TBL] [Abstract][Full Text] [Related]
18. Regulation of CDK7-carboxyl-terminal domain kinase activity by the tumor suppressor p16(INK4A) contributes to cell cycle regulation.
Nishiwaki E; Turner SL; Harju S; Miyazaki S; Kashiwagi M; Koh J; Serizawa H
Mol Cell Biol; 2000 Oct; 20(20):7726-34. PubMed ID: 11003668
[TBL] [Abstract][Full Text] [Related]
19. Xylocydine, a novel Cdk inhibitor, is an effective inducer of apoptosis in hepatocellular carcinoma cells in vitro and in vivo.
Cho SJ; Lee SS; Kim YJ; Park BD; Choi JS; Liu L; Ham YM; Moon Kim B; Lee SK
Cancer Lett; 2010 Jan; 287(2):196-206. PubMed ID: 19616371
[TBL] [Abstract][Full Text] [Related]
20. Loop flexibility and solvent dynamics as determinants for the selective inhibition of cyclin-dependent kinase 4: comparative molecular dynamics simulation studies of CDK2 and CDK4.
Park H; Yeom MS; Lee S
Chembiochem; 2004 Dec; 5(12):1662-72. PubMed ID: 15505811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
